Use of saliva-based nano-biochip tests for acute myocardial infarction at the point of care: A feasibility study

Pierre N. Floriano, Nicolaos Christodoulides, Craig S. Miller, Jeffrey L. Ebersole, John Spertus, Beate G. Rose, Denis F. Kinane, M. John Novak, Steven Steinhubl, Shelley Acosta, Sanghamitra Mohanty, Priya Dharshan, Chih Ko Yeh, Spencer Redding, Wieslaw Furmaga, John T. McDevitt

Research output: Contribution to journalArticle

120 Scopus citations

Abstract

BACKGROUND: For adults with chest pain, the electrocardiogram (ECG) and measures of serum biomarkers are used to screen and diagnose myocardial necrosis. These measurements require time that can delay therapy and affect prognosis. Our objective was to investigate the feasibility and utility of saliva as an alternative diagnostic fluid for identifying biomarkers of acute myocardial infarction (AMI). METHODS: We used Luminex and lab-on-a-chip methods to assay 21 proteins in serum and unstimulated whole saliva procured from 41 AMI patients within 48 h of chest pain onset and from 43 apparently healthy controls. Data were analyzed by use of logistic regression and area under curve (AUC) for ROC analysis to evaluate the diagnostic utility of each biomarker, or combinations of biomarkers, in screening for AMI. RESULTS: Both established and novel cardiac biomarkers demonstrated significant differences in concentrations between patients with AMI and controls without AMI. The saliva-based biomarker panel of C-reactive protein, myoglobin, and myeloperoxidase exhibited significant diagnostic capability (AUC = 0.85, P < 0.0001) and in conjunction with ECG yielded strong screening capacity for AMI (AUC = 0.96) comparable to that of the panel (brain natriuretic peptide, troponin-I, creatine kinase-MB, myoglobin; AUC = 0.98) and far exceeded the screening capacity of ECG alone (AUC approximately 0.6). En route to translating these findings to clinical practice, we adapted these unstimulated whole saliva tests to a novel lab-on-a-chip platform for proof-of-principle screens for AMI. CONCLUSIONS: Complementary to ECG, saliva-based tests within lab-on-a-chip systems may provide a convenient and rapid screening method for cardiac events in prehospital stages for AMI patients.

Original languageEnglish (US)
Pages (from-to)1530-1538
Number of pages9
JournalClinical Chemistry
Volume55
Issue number8
DOIs
StatePublished - Aug 1 2009

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Biochemistry, medical

Fingerprint Dive into the research topics of 'Use of saliva-based nano-biochip tests for acute myocardial infarction at the point of care: A feasibility study'. Together they form a unique fingerprint.

  • Cite this

    Floriano, P. N., Christodoulides, N., Miller, C. S., Ebersole, J. L., Spertus, J., Rose, B. G., Kinane, D. F., Novak, M. J., Steinhubl, S., Acosta, S., Mohanty, S., Dharshan, P., Yeh, C. K., Redding, S., Furmaga, W., & McDevitt, J. T. (2009). Use of saliva-based nano-biochip tests for acute myocardial infarction at the point of care: A feasibility study. Clinical Chemistry, 55(8), 1530-1538. https://doi.org/10.1373/clinchem.2008.117713